We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Mallinckrodt has hit a snag in its quest to bring an abuse-deterrent version of Roxicodone (oxycodone hydrochloride) to market in the US, as it emerges that the FDA saw fit to reject the opioid...